Monitor upcoming regulatory submissions for ocular MG and anti-AChR-negative MG label expansions, which could drive revenue growth. Also watch for empasiprubart Phase 3 data in CIDP (EMNERGIZE/EMVIGORATE) and adimanebart Phase 2/3 in CMS/SMA as pipeline catalysts.
Price Chart
Executive Summary
argenx presented a broad set of clinical data at the 2026 AANEM and MGFA meetings, including Phase 3 ADAPT OCULUS results showing deepening improvements in ocular MG, one-year sustained efficacy in anti-AChR antibody-negative MG from ADAPT SERON, and long-term safety/efficacy in CIDP from ADHERE/ADHERE+ with follow-up beyond five years. Real-world evidence from over 1,100 U.S. MG patients supports earlier VYVGART initiation, and Phase 2 ARDA+ data for empasiprubart in MMN showed sustained benefit. The data reinforce VYVGART's expanding label potential and pipeline progress, but no new financial guidance or revenue figures were disclosed.
Key Facts
- Phase 3 ADAPT OCULUS: after two additional VYVGART cycles, mean MGII ocular scores improved from -4.5 to -6.8 in AChR-Ab-positive patients and from -2.7 to -4.5 in triple-seronegative patients.
- ADAPT SERON: one-year sustained efficacy in anti-AChR antibody-negative gMG with ~5-point MG-ADL improvement maintained through Week 52.
- Real-world analysis of >1,100 U.S. MG patients: those treated within 1 year of diagnosis had mean MG-ADL reduction of 4.7 points vs 3.5 points for >3 years; 50% reached minimal symptom expression (p<0.001).
- CIDP ADHERE/ADHERE+ interim analysis: ~40% of responding participants reached INCAT score 0 or 1 during extension; follow-up beyond 5 years.
- CIDP grip strength: VYVGART Hytrulo reduced relative risk of deterioration by 71.5% (HR 0.285; p<0.001).
- Phase 4 CIDP switch study: 87% of patients remained on VYVGART Hytrulo through 12 weeks after one-week transition from IVIg.
- CIDP first-line: 87.5% of treatment-naïve patients achieved confirmed clinical improvement; 44.4% improved by ≥2 INCAT points.
- Phase 2 ARDA+ for empasiprubart in MMN: sustained clinical benefit and consistent safety.
- Phase 1b adimanebart in DOK7-CMS: improvements in walking performance via digital gait outcomes.
Financial Impact
No financial figures disclosed; data support potential label expansion into ocular MG, anti-AChR-negative MG, and earlier treatment paradigms, which could expand VYVGART's addressable patient population.
Risk Factors
- Regulatory approval for ocular MG and anti-AChR-negative MG is not guaranteed; FDA may require additional trials.
- Competition from other FcRn inhibitors (e.g., UCB's rozanolixizumab, Johnson & Johnson's nipocalimab) could limit market share.
- Empasiprubart and adimanebart are early-stage; clinical failure in later-stage trials would reduce pipeline optionality.
- Real-world evidence may not replicate in controlled settings; payer reimbursement for earlier treatment lines is uncertain.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-111631 |
| Document: tm2626570d1_6k.htm | 0001104659-26-111631 |
| Document: 0001104659-26-111631-index-headers.html | 0001104659-26-111631 |
| Document: 0001104659-26-111631-index.html | 0001104659-26-111631 |
| Document: 0001104659-26-111631.txt | 0001104659-26-111631 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 6-K | $875.76 | awaiting T+20 | — | $882.48 (+0.77%) |
Oct 19, 2026 8d ago | 6-K | $825.61 | awaiting T+20 | — | $882.48 (+6.89%) |
Oct 8, 2026 19d ago | 6-K | $818.63 | awaiting T+20 | — | $882.48 (+7.80%) |
Sep 29, 2026 28d ago | 6-K | $970.66 $871.52 | ▼ −10.21% | ▼ −10.87% | $882.48 (−9.08%) |
Sep 10, 2026 6w ago | Institutional Cluster | $984.04 $818.63 | ▼ −16.81% | ▼ −18.93% | $882.48 (−10.32%) |
Aug 17, 2026 10w ago | 6-K | $987.84 $990.54 | ▲ +0.27% | ▲ +1.80% | $882.48 (−10.67%) |
Aug 6, 2026 11w ago | Press Release | $875.30 $1,053.46 | ▲ +20.35% | ▲ +19.75% | $882.48 (+0.82%) |
Jul 27, 2026 13w ago | 6-K | $888.82 $1,011.11 | ▲ +13.76% | ▲ +10.46% | $882.48 (−0.71%) |
Jul 27, 2026 13w ago | Press Release | $888.82 $1,011.11 | ▲ +13.76% | ▲ +10.46% | $882.48 (−0.71%) |
Jul 23, 2026 13w ago | Press Release | $924.60 $1,038.12 | ▲ +12.28% | ▲ +8.97% | $882.48 (−4.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers